DOCSLIB.ORG

Promoter Hypermethylation of FBXO32, a Novel TGF-Β&Sol;SMAD4 Target Gene and Tumor Suppressor, Is Associated with P

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Promoter Hypermethylation of FBXO32, a Novel TGF-Β&Sol;SMAD4 Target Gene and Tumor Suppressor, Is Associated with P Laboratory Investigation (2010) 90, 414–425 & 2010 USCAP, Inc All rights reserved 0023-6837/10 $32.00 Promoter hypermethylation of FBXO32, a novel TGF-b/ SMAD4 target gene and tumor suppressor, is associated with poor prognosis in human ovarian cancer Jian-Liang Chou1,2, Her-Young Su3, Lin-Yu Chen1,2, Yu-Ping Liao4, Corinna Hartman-Frey5, Yi-Hui Lai1,2, Hui-Wen Yang1,2, Daniel E Deatherage6, Chieh-Ti Kuo6, Yi-Wen Huang6, Pearlly S Yan6, Shu-Huei Hsiao1,7, Chien-Kuo Tai1,2, Huey-Jen L Lin6,8, Ramana V Davuluri9, Tai-Kuang Chao10, Kenneth P Nephew5, Tim H-M Huang6, Hung-Cheng Lai*,3,11 and Michael W-Y Chan*,1,7 Resistance to TGF-b is frequently observed in ovarian cancer, and disrupted TGF-b/SMAD4 signaling results in the aberrant expression of downstream target genes in the disease. Our previous study showed that ADAM19, a SMAD4 target gene, is downregulated through epigenetic mechanisms in ovarian cancer with aberrant TGF-b/SMAD4 signaling. In this study, we investigated the mechanism of downregulation of FBXO32, another SMAD4 target gene, and the clinical significance of the loss of FBXO32 expression in ovarian cancer. Expression of FBXO32 was observed in the normal ovarian surface epithelium, but not in ovarian cancer cell lines. FBXO32 methylation was observed in ovarian cancer cell lines displaying constitutive TGF-b/SMAD4 signaling, and epigenetic drug treatment restored FBXO32 expression in ovarian cancer cell lines regardless of FBXO32 methylation status, suggesting that epigenetic regulation of this gene in ovarian cancer may be a common event. In advanced-stage ovarian tumors, a significant (29.3%; Po0.05) methylation frequency of FBXO32 was observed and the association between FBXO32 methylation and shorter progression-free survival was significant, as determined by both Kaplan–Meier analysis (Po0.05) and multivariate Cox regression analysis (hazard ratio: 1.003, Po0.05). Reexpression of FBXO32 markedly reduced proliferation of a platinum-resistant ovarian cancer cell line both in vitro and in vivo, due to increased apoptosis of the cells, and resensitized ovarian cancer cells to cisplatin. In conclusion, the novel tumor suppressor FBXO32 is epigenetically silenced in ovarian cancer cell lines with disrupted TGF- b/SMAD4 signaling, and FBXO32 methylation status predicts survival in patients with ovarian cancer. Laboratory Investigation (2010) 90, 414–425; doi:10.1038/labinvest.2009.138; published online 11 January 2010 KEYWORDS: ovarian cancer; epigenetics; TGF-b; FBXO32 Ovarian cancer is the fifth leading cause of death in women ease. Despite advances in chemotherapy, the poor prognosis and the most deadly of gynecological malignancies.1 The for patients with ovarian cancer is reflected in the o20% lifetime risk of ovarian cancer in women is B1.5%.2 As 5-year survival rate after initial diagnosis for patients with ovarian cancer has few symptoms early in its course, the stage III and IV disease, whereas survival of patients with majority of patients are diagnosed with advanced-stage dis- stage I or II disease is 480% for the same period.3 Current 1Department of Life Science, National Chung Cheng University, Min-Hsiung, Chia-Yi, Taiwan, ROC; 2Institute of Molecular Biology, National Chung Cheng University, Min-Hsiung, Chia-Yi, Taiwan, ROC; 3Graduate Institute of Medical Sciences, National Defense Medical Center, Taipei, Taiwan, ROC; 4Graduate Institute of Life Sciences, National Defense Medical Center, Taipei, Taiwan, ROC; 5Department of Medical Sciences, Indiana University School of Medicine, Bloomington, IN, USA; 6Department of Molecular Virology, Immunology, and Medical Genetics, Human Cancer Genetics Program, Comprehensive Cancer Center, the Ohio State University, Columbus, OH, USA; 7Human Epigenomics Center, National Chung Cheng University, Min-Hsiung, Chia-Yi, Taiwan, ROC; 8Divison of Medical Technology, School of Allied Medical Professions, the Ohio State University, Columbus, OH, USA; 9Center for Systems and Computational Biology, Molecular and Cellular Oncogenesis Program, The Wistar Institute, Philadelphia, PA, USA; 10Department of Pathology, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan, ROC and 11Department of Obstetrics and Gynecology, National Defense Medical Center, Taipei, Taiwan, ROC *Correspondence: Dr MWY Chan, PhD, Room 452, Department of Life Science and Human Epigenomics Center, 168 University Road, National Chung Cheng University, Min-Hsiung, Chia-Yi, 621, Taiwan, ROC. E-mail: [email protected] or Dr H-C Lai, MD, PhD, Department of Obstetrics and Gynecology, Tri-Service General Hospital, National Defense Medical Center, 5F, 325, Sec 2, Cheng-Gong Rd., Neihu District, Taipei 114, Taiwan, ROC. E-mail: [email protected] Received 30 April 2009; revised 3 November 2009; accepted 23 November 2009 414 Laboratory Investigation | Volume 90 March 2010 | www.laboratoryinvestigation.org Epigenetic dysregulation of FBXO32 J-L Chou et al prognostic indicators using clinicopathological variables, MATERIALS AND METHODS including stage and grade, neither accurately predict clinical Patient Samples outcomes nor provide biological insight into the disease. A total of 96 ovarian cancer samples were obtained from the Thus, a better understanding of the molecular carcinogenesis Tri-Service General Hospital (Taipei, Taiwan) (Supplemen- of ovarian cancer is required for developing more reliable tary Table S1). Five normal OSE (NOSE) cells were acquired prognostic markers. from patients during surgery for benign gynecological disease The transforming growth factor-b signaling pathway has at the Indiana University as described previously.17,25 All an important role in controlling proliferation, differentiation, studies involving human ovarian epithelial samples were and other cellular processes, including the growth of ovarian approved by the Institutional Review Boards of the Tri-Ser- surface epithelial (OSE) cells.4 With each ovulation, the OSE vice General Hospital (Taiwan) and the Indiana University. covering the ovary undergoes rupture, followed by pro- 5 liferation-mediated repair. The growth inhibitory effect of Cell Culture and Epigenetic Treatment TGF-b on the OSE may have a key role in preventing over- 5 Immortalized OSE (IOSE) cells were derived by transducing proliferation of OSE, and dysregulation of TGF-b signaling the catalytic subunit of human telomerase and the papilloma may be crucial to the development of epithelial ovarian virus subunit E7 into primary ovarian epithelial cells, as cancer. In addition, resistance to TGF-b signaling is com- 26 6,7 described previously. Cells were maintained in a 1:1 mix- monly observed in ovarian cancer, suggesting that dimin- ture of medium 199 (Sigma, St Louis, MO, USA) and 105 ished responsiveness to TGF-b is a key event. However, few (Sigma) supplemented with 10% fetal bovine serum (FBS) studies have examined the consequences of disrupted TGF-b (Invitrogen, Carlsbad, CA, USA), 400 ng/ml hydrocortisone signaling in ovarian cancer. (Sigma), 10 ng/ml EGF, and 50 Units/ml of penicillin/strep- Ovarian tumorigenesis is a multistep process that includes tomycin (Invitrogen).26 Ovarian cancer cell lines, namely the accumulation of acquired (somatic) epigenetic changes in 8 A2780, CP70, MCP2, MCP3, were propagated with RPMI critical genes. Epigenetic alterations, including DNA methyl- 1640 (Invitrogen) containing 10% FBS. The HeyC2 cell was ation and histone modifications, have important roles in 9–11 12–16 cultured with DMEM containing 5% FBS, 1% NEAA, 1% gene regulation, and we along with others have Gln, and 1% HEPES. The SKOV3 cell was cultured previously shown that tumor-suppressor genes can be tran- with McCoy’s 5A containing 10% FBS, 1% NEAA, 1% Gln, scriptionally silenced by epigenetic modifications in ovarian and 1% HEPES. For epigenetic treatment, 1 Â 106 cells were cancer. We have also shown that epigenetically modified seeded onto 90-mm plates and treated with 5 mM50-aza-20- genes can be used for both ovarian cancer diagnosis and 17,18 deoxycytidine (5-azaDC; Sigma) for 72 h or with trichostatin prognosis. A (TSA, 0.5 mM; Sigma) for 12 h. For 5-azaDC treatment, Our previous study using chromatin immunoprecipitation media were changed and a new drug was added every 24 h. microarray (ChIP–Chip) identified FBXO32 as a TGF-b/SMAD target gene in OSE.19 FBXO32 (also known as atrogin-1) is a member of the F-box protein family and constitutes one of the DNA Extraction four subunits of the ubiquitin protein ligase complex.20,21 The DNA was extracted using the Tissue and Cell Genomic DNA FBXO32 protein has been reported to have a role in muscle Purification Kit (Genemark, Taiwan). DNA was eluted in 1 atrophy,22 and recent findings suggest that FBXO32 is a novel 50 ml distilled water and stored at À20 C until use. apoptosis regulator23 and is negatively regulated by a pro- survival signal.24 Interestingly, Tan et al23 also showed that Bisulfite Conversion and Combined Bisulfite Restriction FBXO32 was transcriptionally silenced by epigenetic mechan- Analysis isms in MCF-7 breast cancer cells. In this study, we found that Genomic DNA (0.5 mg) was bisulfite modified using the EZ FBXO32 was downregulated in a panel of ovarian cancer cell DNA Methylation Kit (Zymo Research, Orange, CA, USA) lines. Promoter hypermethylation of FBXO32 was observed in according to the manufacturer’s protocol. For combined bi- ovarian cancer cells, showing constitutive SMAD4 nuclear sulfite restriction analysis (COBRA), bisulfite-modified DNA translocation.15
Load more

Recommended publications
  • FBXO32 Promotes Microenvironment Underlying Epithelial-Mesenchymal Transition Via Ctbp1 During Tumour Metastasis and Brain Development
    FBXO32 promotes microenvironment underlying epithelial- mesenchymal transition via CtBP1 during tumour metastasis and brain development Sahu, S. K., Tiwari, N., Pataskar, A., Zhuang, Y., Borisova, M., Diken, M., Strand, S., Beli, P., & Tiwari, V. K. (2017). FBXO32 promotes microenvironment underlying epithelial-mesenchymal transition via CtBP1 during tumour metastasis and brain development. Nature Communications, 8(1), [1523]. https://doi.org/10.1038/s41467-017-01366-x Published in: Nature Communications Document Version: Publisher's PDF, also known as Version of record Queen's University Belfast - Research Portal: Link to publication record in Queen's University Belfast Research Portal Publisher rights Copyright 2017 the authors. This is an open access article published under a Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium, provided the author and source are cited. General rights Copyright for the publications made accessible via the Queen's University Belfast Research Portal is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights. Take down policy The Research Portal is Queen's institutional repository that provides access to Queen's research output. Every effort has been made to ensure that content in the Research Portal does not infringe any person's rights, or applicable UK laws. If you discover content in the Research Portal that you believe breaches copyright or violates any law, please contact [email protected]. Download date:27. Sep. 2021 ARTICLE DOI: 10.1038/s41467-017-01366-x OPEN FBXO32 promotes microenvironment underlying epithelial-mesenchymal transition via CtBP1 during tumour metastasis and brain development Sanjeeb Kumar Sahu1, Neha Tiwari2, Abhijeet Pataskar1, Yuan Zhuang1, Marina Borisova1, Mustafa Diken3, Susanne Strand4, Petra Beli1 & Vijay K.
    [Show full text]
  • Anti-FBXO32 Antibody (ARG55503)
    Product datasheet [email protected] ARG55503 Package: 100 μl anti-FBXO32 antibody Store at: -20°C Summary Product Description Rabbit Polyclonal antibody recognizes FBXO32 Tested Reactivity Ms Predict Reactivity Hu, Rat Tested Application WB Host Rabbit Clonality Polyclonal Isotype IgG Target Name FBXO32 Antigen Species Human Immunogen Recombinant protein of Human FBXO32 Conjugation Un-conjugated Alternate Names Muscle atrophy F-box protein; Atrogin-1; F-box only protein 32; Fbx32; MAFbx Application Instructions Application table Application Dilution WB 1:500 - 1:2000 Application Note * The dilutions indicate recommended starting dilutions and the optimal dilutions or concentrations should be determined by the scientist. Positive Control Mouse heart Calculated Mw 42 kDa Properties Form Liquid Purification Affinity purification with immunogen. Buffer PBS (pH 7.3), 0.02% Sodium azide and 50% Glycerol Preservative 0.02% Sodium azide Stabilizer 50% Glycerol Storage instruction For continuous use, store undiluted antibody at 2-8°C for up to a week. For long-term storage, aliquot and store at -20°C. Storage in frost free freezers is not recommended. Avoid repeated freeze/thaw cycles. Suggest spin the vial prior to opening. The antibody solution should be gently mixed before use. Note For laboratory research only, not for drug, diagnostic or other use. www.arigobio.com 1/2 Bioinformation Database links GeneID: 67731 Mouse Swiss-port # Q9CPU7 Mouse Gene Symbol FBXO32 Gene Full Name F-box protein 32 Background This gene encodes a member of the F-box protein family which is characterized by an approximately 40 amino acid motif, the F-box. The F-box proteins constitute one of the four subunits of the ubiquitin protein ligase complex called SCFs (SKP1-cullin-F-box), which function in phosphorylation-dependent ubiquitination.
    [Show full text]
  • Satellite Cell Senescence Underlies Myopathy in a Mouse Model of Limb-Girdle Muscular Dystrophy 2H Elena Kudryashova, Irina Kramerova, and Melissa J
    Research article Satellite cell senescence underlies myopathy in a mouse model of limb-girdle muscular dystrophy 2H Elena Kudryashova, Irina Kramerova, and Melissa J. Spencer Department of Neurology, Center for Duchenne Muscular Dystrophy at UCLA, David Geffen School of Medicine at UCLA, Los Angeles, California, USA. Mutations in the E3 ubiquitin ligase tripartite motif-containing 32 (TRIM32) are responsible for the disease limb-girdle muscular dystrophy 2H (LGMD2H). Previously, we generated Trim32 knockout mice (Trim32–/– mice) and showed that they display a myopathic phenotype accompanied by neurogenic features. Here, we used these mice to investigate the muscle-specific defects arising from the absence of TRIM32, which underlie the myopathic phenotype. Using 2 models of induced atrophy, we showed that TRIM32 is dispensable for muscle atrophy. Conversely, TRIM32 was necessary for muscle regrowth after atrophy. Furthermore, TRIM32-defi- cient primary myoblasts underwent premature senescence and impaired myogenesis due to accumulation of PIAS4, an E3 SUMO ligase and TRIM32 substrate that was previously shown to be associated with senescence. Premature senescence of myoblasts was also observed in vivo in an atrophy/regrowth model. Trim32–/– muscles had substantially fewer activated satellite cells, increased PIAS4 levels, and growth failure compared with wild- type muscles. Moreover, Trim32–/– muscles exhibited features of premature sarcopenia, such as selective type II fast fiber atrophy. These results imply that premature senescence of muscle satellite cells is an underlying pathogenic feature of LGMD2H and reveal what we believe to be a new mechanism of muscular dystrophy associated with reductions in available satellite cells and premature sarcopenia. Introduction and are primarily characterized by proximal muscle weakness and Tripartite motif-containing 32 (TRIM32) is a member of the tri- wasting.
    [Show full text]
  • Full Text (PDF)
    Published OnlineFirst August 29, 2012; DOI: 10.1158/1078-0432.CCR-12-0873 Clinical Cancer Cancer Therapy: Preclinical Research Superior Efficacy of a Combined Epigenetic Therapy against Human Mantle Cell Lymphoma Cells Warren Fiskus1, Rekha Rao1, Ramesh Balusu1, Siddhartha Ganguly1, Jianguo Tao2, Eduardo Sotomayor2, Uma Mudunuru1, Jacqueline E. Smith1, Stacey L. Hembruff1, Peter Atadja3, Victor E. Marquez4, and Kapil Bhalla1 Abstract Purpose: A deregulated epigenome contributes to the transformed phenotype of mantle cell lymphoma (MCL). This involves activity of the polycomb repressive complex (PRC) 2, containing three core proteins, EZH2, SUZ12, and EED, in which the SET domain of EZH2 mediates the histone methyltransferase activity. We determined the effects of 3-deazaneplanocin A (DZNep), an S-adeno- sylhomocysteine hydrolase inhibitor, and/or pan-histone deacetylase inhibitor panobinostat (PS) on cultured and primary MCL cells. Experimental Design: Following treatment with DZNep and/or PS, apoptosis and the levels and activity of EZH2 and PRC2 proteins in cultured and primary MCL cells were determined. Results: Treatment with DZNep depleted EZH2, SUZ12, and 3MeK27H3 in the cultured human MCL cells. DZNep also increased expression of p21, p27, and FBXO32, whereas it depleted Cyclin D1 and Cyclin E1 levels in MCL cells. In addition, DZNep treatment induced cell-cycle arrest and apoptosis in cultured and primary MCL cells. Furthermore, as compared with treatment with each agent alone, cotreatment with DZNep and PS caused greater depletion of EZH2, SUZ12, 3MeK27H3, and Cyclin D1 levels, whereas it induced greater expression of FBXO32, p16, p21, and p27. Combined treatment with DZNep and PS synergistically induced apoptosis of cultured and primary MCL cells while relatively sparing normal CD34 þ cells.
    [Show full text]
  • A Substitution Mutation in Cardiac Ubiquitin Ligase, FBXO32, Is Associated with an Autosomal Recessive Form of Dilated Cardiomyopathy Zuhair N
    Al-Hassnan et al. BMC Medical Genetics (2016) 17:3 DOI 10.1186/s12881-016-0267-5 RESEARCH ARTICLE Open Access A substitution mutation in cardiac ubiquitin ligase, FBXO32, is associated with an autosomal recessive form of dilated cardiomyopathy Zuhair N. Al-Hassnan1,2,7,8*, Zarghuna MA. Shinwari1, Salma M. Wakil3, Sahar Tulbah1, Shamayel Mohammed4, Zuhair Rahbeeni2, Mohammed Alghamdi4, Monther Rababh1, Dilek Colak5, Namik Kaya3, Majid Al-Fayyadh1,6 and Jehad Alburaiki6 Abstract Background: Familial dilated cardiomyopathy (DCM) is genetically heterogeneous. Mutations in more than 40 genes have been identified in familial cases, mostly inherited in an autosomal dominant pattern. DCM due to recessive mutations is rarely observed. In consanguineous families, homozygosity mapping and whole exome sequencing (WES) can be utilized to identify the genetic defects in recessively inherited DCM. Methods: In a consanguineous family with four affected siblings with severe DCM, we combined homozygosity mapping, linkage analysis and WES, to uncover the genetic defect. Results: A region of homozygosity (ROH) on chromosome 8q24.13–24.23 was found to be shared by all of the four affected siblings. WES detected ~47,000 variants that were filtered to a homozygous mutation (p.Gly243Arg) in the FBXO32 gene, located within the identified ROH. The mutation segregated with the phenotype, replaced a highly- conserved amino acid, and was not detected in 1986 ethnically-matched chromosomes. FBXO32, which encodes a muscle-specific ubiquitin ligase, has been implicated in the pathogenesis of cardiomyopathy through the ubiquitin proteasome system (UPS). In addition, FBXO32-knockout mice manifest with cardiomyopathy. Screening the index patient for all of the WES variants in 48 genes known to be implicated in hypertrophic and dilated cardiomyopathy was negative.
    [Show full text]
  • Targeting the DEK Oncogene in Head and Neck Squamous Cell Carcinoma: Functional and Transcriptional Consequences
    Targeting the DEK oncogene in head and neck squamous cell carcinoma: functional and transcriptional consequences A dissertation submitted to the Graduate School of the University of Cincinnati in partial fulfillment of the requirements to the degree of Doctor of Philosophy (Ph.D.) in the Department of Cancer and Cell Biology of the College of Medicine March 2015 by Allie Kate Adams B.S. The Ohio State University, 2009 Dissertation Committee: Susanne I. Wells, Ph.D. (Chair) Keith A. Casper, M.D. Peter J. Stambrook, Ph.D. Ronald R. Waclaw, Ph.D. Susan E. Waltz, Ph.D. Kathryn A. Wikenheiser-Brokamp, M.D., Ph.D. Abstract Head and neck squamous cell carcinoma (HNSCC) is one of the most common malignancies worldwide with over 50,000 new cases in the United States each year. For many years tobacco and alcohol use were the main etiological factors; however, it is now widely accepted that human papillomavirus (HPV) infection accounts for at least one-quarter of all HNSCCs. HPV+ and HPV- HNSCCs are studied as separate diseases as their prognosis, treatment, and molecular signatures are distinct. Five-year survival rates of HNSCC hover around 40-50%, and novel therapeutic targets and biomarkers are necessary to improve patient outcomes. Here, we investigate the DEK oncogene and its function in regulating HNSCC development and signaling. DEK is overexpressed in many cancer types, with roles in molecular processes such as transcription, DNA repair, and replication, as well as phenotypes such as apoptosis, senescence, and proliferation. DEK had never been previously studied in this tumor type; therefore, our studies began with clinical specimens to examine DEK expression patterns in primary HNSCC tissue.
    [Show full text]
  • And Brain-Specific Expression of KLHL Family Genes
    International Journal of Molecular Sciences Article Epigenetics of Muscle- and Brain-Specific Expression of KLHL Family Genes Kenneth C. Ehrlich 1, Carl Baribault 2 and Melanie Ehrlich 3,* 1 Center for Biomedical Informatics and Genomics, Tulane University Health Sciences Center, New Orleans, LA 70112, USA; [email protected] 2 Center for Research and Scientific Computing (CRSC), Tulane University Information Technology, Tulane University, New Orleans, LA 70112, USA; [email protected] 3 Center for Biomedical Informatics and Genomics, Tulane Cancer Center, Hayward Genetics Program, Tulane University Health Sciences Center, New Orleans, LA 70112, USA * Correspondence: [email protected]; Tel.: +1-504-939-0916 Received: 16 October 2020; Accepted: 6 November 2020; Published: 9 November 2020 Abstract: KLHL and the related KBTBD genes encode components of the Cullin-E3 ubiquitin ligase complex and typically target tissue-specific proteins for degradation, thereby affecting differentiation, homeostasis, metabolism, cell signaling, and the oxidative stress response. Despite their importance in cell function and disease (especially, KLHL40, KLHL41, KBTBD13, KEAP1, and ENC1), previous studies of epigenetic factors that affect transcription were predominantly limited to promoter DNA methylation. Using diverse tissue and cell culture whole-genome profiles, we examined 17 KLHL or KBTBD genes preferentially expressed in skeletal muscle or brain to identify tissue-specific enhancer and promoter chromatin, open chromatin (DNaseI hypersensitivity), and DNA hypomethylation. Sixteen of the 17 genes displayed muscle- or brain-specific enhancer chromatin in their gene bodies, and most exhibited specific intergenic enhancer chromatin as well. Seven genes were embedded in super-enhancers (particularly strong, tissue-specific clusters of enhancers). The enhancer chromatin regions typically displayed foci of DNA hypomethylation at peaks of open chromatin.
    [Show full text]
  • Ubiquitin Ligases at the Heart of Skeletal Muscle Atrophy Control
    molecules Review Ubiquitin Ligases at the Heart of Skeletal Muscle Atrophy Control Dulce Peris-Moreno , Laura Cussonneau, Lydie Combaret ,Cécile Polge † and Daniel Taillandier *,† Unité de Nutrition Humaine (UNH), Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Université Clermont Auvergne, F-63000 Clermont-Ferrand, France; [email protected] (D.P.-M.); [email protected] (L.C.); [email protected] (L.C.); [email protected] (C.P.) * Correspondence: [email protected] † These authors contributed equally to the work. Abstract: Skeletal muscle loss is a detrimental side-effect of numerous chronic diseases that dramati- cally increases mortality and morbidity. The alteration of protein homeostasis is generally due to increased protein breakdown while, protein synthesis may also be down-regulated. The ubiquitin proteasome system (UPS) is a master regulator of skeletal muscle that impacts muscle contractile properties and metabolism through multiple levers like signaling pathways, contractile apparatus degradation, etc. Among the different actors of the UPS, the E3 ubiquitin ligases specifically target key proteins for either degradation or activity modulation, thus controlling both pro-anabolic or pro-catabolic factors. The atrogenes MuRF1/TRIM63 and MAFbx/Atrogin-1 encode for key E3 ligases that target contractile proteins and key actors of protein synthesis respectively. However, several other E3 ligases are involved upstream in the atrophy program, from signal transduction control to modulation of energy balance. Controlling E3 ligases activity is thus a tempting approach for preserving muscle mass. While indirect modulation of E3 ligases may prove beneficial in some situations of muscle atrophy, some drugs directly inhibiting their activity have started to appear.
    [Show full text]
  • 1 Supplementary Information ADCK2 Haploinsufficiency Reduces
    Supplementary information ADCK2 haploinsufficiency reduces mitochondrial lipid oxidation and causes myopathy associated with CoQ deficiency.. Luis Vázquez-Fonseca1,8,§, Jochen Schäfer2,§, Ignacio Navas-Enamorado1,7, Carlos Santos-Ocaña1,10, Juan D. Hernández-Camacho1,10, Ignacio Guerra1, María V. Cascajo1,10, Ana Sánchez-Cuesta1,10, Zoltan Horvath2#, Emilio Siendones1, Cristina Jou3,10, Mercedes Casado3,10, Purificación Gutiérrez1, Gloria Brea-Calvo1,10, Guillermo López-Lluch1,10, Daniel M. Fernández-Ayala1,10, Ana B. Cortés- Rodríguez1,10, Juan C. Rodríguez-Aguilera1,10, Cristiane Matté4, Antonia Ribes5,10, Sandra Y. Prieto- Soler6, Eduardo Dominguez-del-Toro6, Andrea di Francesco8, Miguel A. Aon8, Michel Bernier8, Leonardo Salviati9, Rafael Artuch3,10, Rafael de Cabo8, Sandra Jackson2 and Plácido Navas1,10 1 Supplementary Results Case report The male index patient (subject II-3, Fig. S1A) presented to our clinic at 45 years of age with a 15-year history of slowly progressive muscle weakness and myalgia, which occurred at rest but worsened with exercise. Past medical history was unremarkable except for renal disease of unknown cause in childhood, which spontaneously improved. Family history was negative for neurological disease. On examination, moderate proximal symmetrical myopathy, more pronounced in the arms, was noted and the patient was unable to lift his arms above the horizontal position. The patient had a hyperlordotic, waddling gait and was only able to walk 100 meters without the aid of crutches. Bilateral scapular winging was present, and bilateral atrophy of the biceps, triceps, and quadriceps was noted, whilst the deltoid muscles were well preserved. Calf hypertrophy was present. The Trendelenburg sign was positive, and the patient was unable to rise from squatting.
    [Show full text]
  • Mechanism of Progression in Cervical Intraepithelial Neoplasia
    Università degli Studi di Ferrara DOTTORATO DI RICERCA IN SCIENZE BIOMEDICHE CICLO XXVII COORDINATORE Prof. Silvano Capitani Mechanism of progression in cervical intraepithelial neoplasia Settore Scientifico Disciplinare BIO/13 Dottorando Tutore Dott. John Charles Rotondo Prof. Mauro Tognon Anni 2012/2014 INDEX INTRODUCTION 3 OBJECTIVE AND AIMS OF THE STUDY 25 MATERIALS AND METHODS 26 RESULTS 36 DISCUSSION 58 REFERENCES 68 2 INTRODUCTION CERVICAL INTRAEPITHELIAL NEOPLASIA Classification of the cervical intraepithelial neoplasia The cervical intraepithelial neoplasia (CIN) is a pre-cancerous lesion of uterine cervical squamous cell carcinoma (SCC) and is characterized by potentially premalignant transformation and abnormal growth, named dysplasia, of cervical keratinocytes. The histological classification system provides three CIN grades referred to as CIN1 (mild dysplasia), CIN2 (moderate dysplasia) and CIN3 (severe dysplasia) lesions. Each CIN grade remains confined to the cervical epithelium (Figure 1, A, www.lookfordiagnosis.com) and has a variable potential evolution towards the cancer. CIN1 lesions are characterized by keratinocytes with abnormal cell growth, perinuclear cytoplasmic vacuolation, named koilocytosis, and increase volume of the nucleus. This histologic change is confined to the basal third of the cervical epithelium (Figure 1, B). CIN2 lesions, compared to CIN1, are characterized by higher cytologic atypia and cellular disorganization, while koilocytosis is lower or absent. The histological abnormalities are confined to the basal two thirds of the cervical epithelium (Figure 1, C). CIN2 cervical cells show two main features: (i) atypical mitotic figures induced by aneuploidy; (ii) abnormal nucleus/cytoplasm ratio. CIN3 lesions are characterized by keratinocytes endowed with high proliferative index, immaturity and vertical orientation. Abnormal keratinocytes exceed the two thirds of the epithelium or expand throughout the thickness of the epithelium, altering the whole cyto-architecture of the tissue (Figure 1, D).
    [Show full text]
  • Mutation in FBXO32 Causes Dilated Cardiomyopathy Through Up-Regulation of ER-Stress Mediated Apoptosis
    ARTICLE https://doi.org/10.1038/s42003-021-02391-9 OPEN Mutation in FBXO32 causes dilated cardiomyopathy through up-regulation of ER-stress mediated apoptosis Nadya Al-Yacoub1,2, Dilek Colak 3, Salma Awad Mahmoud1, Maya Hammonds 4, Kunhi Muhammed1, ✉ Olfat Al-Harazi3, Abdullah M. Assiri2,5, Jehad Al-Buraiki6, Waleed Al-Habeeb7 & Coralie Poizat1,4,8 Endoplasmic reticulum (ER) stress induction of cell death is implicated in cardiovascular diseases. Sustained activation of ER-stress induces the unfolded protein response (UPR) pathways, which in turn activate three major effector proteins. We previously reported a 1234567890():,; missense homozygous mutation in FBXO32 (MAFbx, Atrogin-1) causing advanced heart failure by impairing autophagy. In the present study, we performed transcriptional profiling and biochemical assays, which unexpectedly revealed a reduced activation of UPR effectors in patient mutant hearts, while a strong up-regulation of the CHOP transcription factor and of its target genes are observed. Expression of mutant FBXO32 in cells is sufficient to induce CHOP-associated apoptosis, to increase the ATF2 transcription factor and to impair ATF2 ubiquitination. ATF2 protein interacts with FBXO32 in the human heart and its expression is especially high in FBXO32 mutant hearts. These findings provide a new underlying mechanism for FBXO32-mediated cardiomyopathy, implicating abnormal activation of CHOP. These results suggest alternative non-canonical pathways of CHOP activation that could be considered to develop new therapeutic targets for the treatment of FBXO32-associated DCM. 1 Cardiovascular Research Program, King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia. 2 Comparative Medicine Department, King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia.
    [Show full text]
  • Association of Genetic Variants of FBXO32 and FOXO6 in the FOXO Pathway with Breast Cancer Risk
    Received: 28 February 2021 | Revised: 26 May 2021 | Accepted: 6 June 2021 DOI: 10.1002/mc.23331 RESEARCH ARTICLE Association of genetic variants of FBXO32 and FOXO6 in the FOXO pathway with breast cancer risk Haijiao Wang1,2,3 | Hongliang Liu2,3 | Lingling Zhao2,3,4 | Sheng Luo5 | Tomi Akinyemiju3 | Shelley Hwang6 | Ying Yue1 | Qingyi Wei2,3,7,8 1Department of Gynecology Oncology, The First Hospital of Jilin University, Changchun, Abstract Jilin, China Forkhead box class O (FOXO) transcription factors play a pivotal role in regulating a 2Duke Cancer Institute, Duke University variety of biological processes, including organismal development, cell signaling, cell Medical Center, Durham, North Carolina, USA 3Department of Population Health Sciences, metabolism, and tumorigenesis. Therefore, we hypothesize that genetic variants in Duke University School of Medicine, Durham, FOXO pathway genes are associated with breast cancer (BC) risk. To test this North Carolina, USA hypothesis, we conducted a large meta‐analysis using 14 published genome‐wide 4Cancer Center, The First Hospital of Jilin University, Changchun, Jilin, China association study (GWAS) data sets in the Discovery, Biology, and Risk of Inherited 5Department of Biostatistics and Variants in Breast Cancer (DRIVE) study. We assessed associations between 5214 Bioinformatics, Duke University School of (365 genotyped in DRIVE and 4849 imputed) common single‐nucleotide poly- Medicine, Durham, North Carolina, USA morphisms (SNPs) in 55 FOXO pathway genes and BC risk. After multiple com- 6Department of Surgery, Duke University School of Medicine, Durham, parison corrections by the Bayesian false‐discovery probability method, we found North Carolina, USA five SNPs to be significantly associated with BC risk.
    [Show full text]